PDF(Pubmed)
Abstract：
OBJECTIVE: The Japanese Interventional oncology group (JIVROSG) showed the efficacy and safety of nonselective transarterial chemoembolization (TACE) with fine cisplatin powder (diamminedichloroplatinum; DDP-H) (65 mg/m2) and porous gelatin particles (DDP-H TACE) without lipiodol for extensive multifocal hepatocellular carcinoma (HCC). However, there are no studies on this method following the JIVROSG study. Therefore, we aimed to evaluate the efficacy of this new DDP-H TACE and its effect on liver function.
METHODS: We retrospectively reviewed the medical records of TACE-naïve patients with multifocal HCC (Child-Pugh class A, up-to-seven out, no prior history of systemic therapy) who underwent whole-liver DDP-H TACE between January 2006 and December 2019.
RESULTS: Sixty patients were included in this study. The median age of the patients was 71 (range, 35-88) years. The median maximum size of tumors was 26 (range, 8-184) mm; 86.7% of patients met the up-to-11 criteria out. The overall survival duration was 30.3 months. At the time of initial evaluation (median, 45 days), the overall response rate was 65.0%; the disease control rate was 86.7% based on the modified response evaluation criteria in solid tumors guideline. Although nine patients\' liver function had deteriorated to Child-Pugh class B at initial evaluation, six of them recovered to Child-Pugh class A. Only three patients (5%) showed permanently impaired liver function.
CONCLUSIONS: Whole-liver DDP-H TACE without lipiodol or beads effectively reduced tumors and preserved liver function.
METHODS: We retrospectively reviewed the medical records of TACE-naïve patients with multifocal HCC (Child-Pugh class A, up-to-seven out, no prior history of systemic therapy) who underwent whole-liver DDP-H TACE between January 2006 and December 2019.
RESULTS: Sixty patients were included in this study. The median age of the patients was 71 (range, 35-88) years. The median maximum size of tumors was 26 (range, 8-184) mm; 86.7% of patients met the up-to-11 criteria out. The overall survival duration was 30.3 months. At the time of initial evaluation (median, 45 days), the overall response rate was 65.0%; the disease control rate was 86.7% based on the modified response evaluation criteria in solid tumors guideline. Although nine patients\' liver function had deteriorated to Child-Pugh class B at initial evaluation, six of them recovered to Child-Pugh class A. Only three patients (5%) showed permanently impaired liver function.
CONCLUSIONS: Whole-liver DDP-H TACE without lipiodol or beads effectively reduced tumors and preserved liver function.
摘要：
目的：日本介入肿瘤学组（JIVROSG）显示了非选择性经肝动脉化疗栓塞（TACE）用顺铂细粉（二氨基二氯铂；DDP-H）（65mg/m2）和不含碘油的多孔明胶颗粒（DDP-HTACE）治疗广泛的多灶性肝细胞癌（HCC）的有效性和安全性。然而,在JIVROSG研究之后，没有关于这种方法的研究。因此,我们旨在评估这种新型DDP-HTACE的疗效及其对肝功能的影响.
方法：我们回顾性回顾了TACE初治多灶性HCC患者的病历（Child-PughA级，多达七个，没有系统治疗史），在2006年1月至2019年12月期间接受了全肝DDP-HTACE。
结果：本研究纳入60例患者。患者的中位年龄为71岁（范围，35-88）年。肿瘤的最大尺寸中位数为26（范围，8-184）毫米；86.7％的患者符合多达11个标准。总生存期为30.3个月。在初步评估时(中位数，45天），总缓解率为65.0%;根据实体肿瘤指南中改良的缓解评估标准,疾病控制率为86.7%.尽管9例患者的肝功能在初步评估时已恶化至Child-PughB级，其中6例恢复到Child-PughA级。只有3例患者（5％）表现出永久性肝功能受损。
结论：全肝DDP-HTACE无碘油或珠可有效减少肿瘤并保留肝功能。
方法：我们回顾性回顾了TACE初治多灶性HCC患者的病历（Child-PughA级，多达七个，没有系统治疗史），在2006年1月至2019年12月期间接受了全肝DDP-HTACE。
结果：本研究纳入60例患者。患者的中位年龄为71岁（范围，35-88）年。肿瘤的最大尺寸中位数为26（范围，8-184）毫米；86.7％的患者符合多达11个标准。总生存期为30.3个月。在初步评估时(中位数，45天），总缓解率为65.0%;根据实体肿瘤指南中改良的缓解评估标准,疾病控制率为86.7%.尽管9例患者的肝功能在初步评估时已恶化至Child-PughB级，其中6例恢复到Child-PughA级。只有3例患者（5％）表现出永久性肝功能受损。
结论：全肝DDP-HTACE无碘油或珠可有效减少肿瘤并保留肝功能。
